-
公开(公告)号：US20240285679A1
公开(公告)日：2024-08-29
申请号：US18573953
申请日：2022-06-22
CPC分类号： A61K33/04 , A61K9/0048 , A61P27/10
摘要： Described herein are compositions and methods for the treatment of vision loss and/or dry eye syndrome. Such compositions comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of such compositions to the inner surface of the eyelid provides therapeutic benefit to patients suffering from vision loss and/or dry eye syndrome.
-
公开(公告)号：US20230399317A1
公开(公告)日：2023-12-14
申请号：US18033055
申请日：2021-10-20
发明人： Charles BOSWORTH , Mark Richard STEWART , Hila BARASH , Nicholas Andrew CHAPMAN , Robert M. BURK , Ian HOLMES , Marc GLEESON , Yair ALSTER , Omer RAFAELI , Jonathan DUNN
IPC分类号： C07D405/06 , A61P27/02 , A61K9/00 , A61K9/08 , C07D409/14 , C07D417/14 , C07D405/14
CPC分类号： C07D405/06 , A61P27/02 , A61K9/0048 , A61K9/08 , C07D409/14 , C07D417/14 , C07D405/14
摘要： Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.
-
公开(公告)号：US20220332749A1
公开(公告)日：2022-10-20
申请号：US17841383
申请日：2022-06-15
发明人： Ian HOLMES , Yair ALSTER , Hila EPSTEIN-BARASH , Charles BOSWORTH , Omer RAFAELI , Robert M. BURK , Marc GLEESON , Mark Richard STEWART , Jonathan DUNN , Alexander James NICHOLLS
摘要： Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.
-
公开(公告)号：US20220332748A1
公开(公告)日：2022-10-20
申请号：US17222802
申请日：2021-04-05
发明人： Ian HOLMES , Yair ALSTER , Hila BARASH , Charles BOSWORTH , Omer RAFAELI , Robert M. BURK , Marc GLEESON , Mark Richard STEWART , Jonathan DUNN , Alexander James NICHOLLS
摘要： Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.
-
公开(公告)号：US20230348517A1
公开(公告)日：2023-11-02
申请号：US18117759
申请日：2023-03-06
发明人： Ian HOLMES , Yair ALSTER , Hila BARASH , Charles BOSWORTH , Omer RAFAELI , Marc GLEESON , Mark Richard STEWART , Jonathan DUNN
CPC分类号： C07H17/00 , A61P27/04 , A61K9/0048 , C07H17/08
摘要： Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory/infections disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugate which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eye, ocular surface or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.
-
公开(公告)号：US20230000675A1
公开(公告)日：2023-01-05
申请号：US17858729
申请日：2022-07-06
发明人： Yair ALSTER , Omer RAFAELI , Marc GLEESON , Charles BOSWORTH , Eitan SHARIFF , Dan TEBOUL
摘要： Provided herein are devices and methods for applying a medicament to an eyelid, e.g. eyelid margin, of a patient while protecting the adjunct ocular tissues such as the cornea.
-
公开(公告)号：US20210401877A1
公开(公告)日：2021-12-30
申请号：US17471111
申请日：2021-09-09
摘要： Provided herein are methods treating a disease or disorder in or around the eye with a pharmaceutical composition comprising selenium disulfide (SeS2) and instructing the treated individual to limit or avoid exposure to light following administration in order to reduce the adverse effect of the composition.
-
公开(公告)号：US20210107899A1
公开(公告)日：2021-04-15
申请号：US17112371
申请日：2020-12-04
发明人： Ian HOLMES , Yair ALSTER , Hila BARASH , Charles BOSWORTH , Omer RAFAELI , Marc GLEESON , Mark Richard STEWART , Robert M. BURK , Jonathan DUNN , Nicholas CHAPMAN
IPC分类号： C07D405/06 , C07D409/14 , C07D405/14 , A61P27/02
摘要： Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.
-
公开(公告)号：US20230357207A1
公开(公告)日：2023-11-09
申请号：US18119248
申请日：2023-03-08
发明人： Ian HOLMES , Yair ALSTER , Hila BARASH , Charles BOSWORTH , Omer RAFAELI , Marc GLEESON , Mark Richard STEWART , Robert M. BURK , Jonathan DUNN , Nicholas CHAPMAN
IPC分类号： C07D405/06 , A61P27/02 , C07D409/14 , C07D405/14
CPC分类号： C07D405/06 , A61P27/02 , C07D409/14 , C07D405/14
摘要： Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.
-
公开(公告)号：US20230346832A1
公开(公告)日：2023-11-02
申请号：US18075161
申请日：2022-12-05
CPC分类号： A61K33/04 , A61K9/0048 , A61K9/06 , A61P27/02
摘要： Provided herein are methods treating a disease or disorder in or around the eye with a pharmaceutical composition comprising selenium disulfide (SeS2) and instructing the treated individual to limit or avoid exposure to light following administration in order to reduce the adverse effect of the composition.
-
-
-
-
-
-
-
-
-
搜索结果
18 条记录 (耗时 0.015 秒)
